FDA Determines Regulatory Review Period for LEVULAN KERASTICK Patent Extension Application

Summary

The US Food and Drug Administration (FDA) has officially announced the regulatory review period for the patent extension of LEVULAN KERASTICK, a human drug product. This determination was made in response to a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.